Lipid Matters

An occasional series of notes on publications or other items dealing with lipid science from a variety of contributors.

30th September 2024

Etomoxir Appears to Lack Assumed Specificity

In full disclosure, I’m posting an article published by a colleague, but I believe it is worth informing the community of lipid scientists of this finding. The article, titled “Etomoxir repurposed as a promiscuous fatty acid mimetic chemoproteomic probe” (Choi et al, iScience Volume 27, Issue 9, 20 September 2024) focuses on assessing the specificity of drug often used to inhibit carnitine palmitoyltransferase I, Cpt1, in order to block mitochondrial fatty acid β-oxidation.  The authors probed the specificity of etomoxir by using click enabled etomoxir probes.  While the click-etomoxir retained its inIn hibitory effect on fatty acid oxidation, it labeled numerous proteins in cells in vitro and in vivo. Many of the identified proteins were involved in the transport and metabolism of fatty acids in the cytoplasm, peroxisome, and mitochondria. Interestingly, by using promiscuous, covalent, and fatty acid mimetic properties of etomoxir, etomoxir targets of fatty acid ω-oxidation were revealed following the loss of the peroxisomal protein Pex5. The study clearly demonstrates that etomoxir is not specific for Cpt1 as previously asserted and shows that much care should be employed when using this tool to distinguish the biological effects of fatty acid oxidation.

Daniel M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA

Archive

2024
2023

Go to older Lipid Matters posts Bill Christie's occasional series of notes on publications or other items dealing with lipid science.